NASDAQ:ANNX Annexon (ANNX) Stock Price, News & Analysis $6.24 +0.07 (+1.13%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.10▼$6.4550-Day Range$4.33▼$6.7952-Week Range$1.57▼$8.40Volume1.18 million shsAverage Volume2.14 million shsMarket Capitalization$576.64 millionP/E RatioN/ADividend YieldN/APrice Target$15.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Annexon alerts: Email Address Annexon MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside145.7% Upside$15.33 Price TargetShort InterestBearish6.32% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.37Based on 3 Articles This WeekInsider TradingAcquiring Shares$16,000 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.94 out of 5 starsMedical Sector654th out of 936 stocksPharmaceutical Preparations Industry304th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAnnexon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnnexon has only been the subject of 4 research reports in the past 90 days.Read more about Annexon's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.32% of the outstanding shares of Annexon have been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Annexon has recently increased by 13.18%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnnexon does not currently pay a dividend.Dividend GrowthAnnexon does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANNX. Previous Next 2.4 News and Social Media Coverage News SentimentAnnexon has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Annexon this week, compared to 2 articles on an average week.Search InterestOnly 13 people have searched for ANNX on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat Follows6 people have added Annexon to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Annexon insiders have bought 40.63% more of their company's stock than they have sold. Specifically, they have bought $16,000.00 in company stock and sold $11,377.00 in company stock.Percentage Held by Insiders12.67% of the stock of Annexon is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Annexon's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Annexon are expected to remain at ($0.98) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annexon is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annexon is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnexon has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Annexon's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWe’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! And how YOU can prepare for the next 2024 BOOM here! About Annexon Stock (NASDAQ:ANNX)Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Read More ANNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANNX Stock News HeadlinesJuly 3, 2024 | insidertrades.comAnnexon, Inc. (NASDAQ:ANNX) Director William H. Carson Purchases 3,200 SharesJuly 21, 2024 | americanbankingnews.comAnnexon (NASDAQ:ANNX) Trading 3.9% Higher July 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.July 16, 2024 | globenewswire.comAnnexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)July 16, 2024 | americanbankingnews.comAnnexon, Inc. (NASDAQ:ANNX) Short Interest Up 27.4% in JuneJuly 11, 2024 | globenewswire.comAnnexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific MeetingJune 25, 2024 | globenewswire.comAnnexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual MeetingJune 17, 2024 | globenewswire.comAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.June 5, 2024 | globenewswire.comAnnexon Announces Pricing of $125 Million Underwritten Public OfferingJune 4, 2024 | globenewswire.comAnnexon Announces Proposed Public Offering of Common StockJune 4, 2024 | reuters.comAnnexon's neurological disorder drug meets main goal of late-stage studyJune 3, 2024 | globenewswire.comAnnexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 DataMay 16, 2024 | globenewswire.comAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)May 14, 2024 | markets.businessinsider.comBuy Rating on Annexon Biosciences Backed by Efficacious ANX007 Data and Meticulous Phase 3 Trial DesignMay 14, 2024 | finance.yahoo.comWe Think Annexon (NASDAQ:ANNX) Can Afford To Drive Business GrowthMay 13, 2024 | globenewswire.comAnnexon Reports First Quarter 2024 Financial Results and Key Anticipated MilestonesMay 9, 2024 | globenewswire.comAnnexon Biosciences to Present at the Bank of America Health Care ConferenceSee More Headlines Receive ANNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANNX CUSIPN/A CIK1528115 Webwww.annexonbio.com Phone650-822-5500Fax650-636-9773Employees60Year FoundedN/APrice Target and Rating Average Stock Price Target$15.33 High Stock Price Target$30.00 Low Stock Price Target$10.00 Potential Upside/Downside+145.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-134,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.52% Return on Assets-46.50% Debt Debt-to-Equity RatioN/A Current Ratio20.61 Quick Ratio20.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.20 per share Price / Book1.95Miscellaneous Outstanding Shares92,410,000Free Float80,704,000Market Cap$577.56 million OptionableOptionable Beta1.29 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Douglas Love Esq. (Age 56)J.D., CEO, President & Director Comp: $980.12kDr. Dean R. Artis Ph.D. (Age 63)Chief Scientific Officer & Executive VP Comp: $797.38kDr. Ted Yednock Ph.D. (Age 66)Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board Comp: $697.76kMs. Jennifer Lew (Age 51)Executive VP, CFO & Corporate Secretary Comp: $624.2kMr. Michael Overdorf M.B.A. (Age 53)Executive VP & Chief Business Officer Comp: $580.47kHenk-Andre Kroon M.D.Senior Vice President of Translational MedicineDr. Jamie Dananberg M.D. (Age 66)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsTheravance BiopharmaNASDAQ:TBPHEnanta PharmaceuticalsNASDAQ:ENTAPliant TherapeuticsNASDAQ:PLRXMaravai LifeSciencesNASDAQ:MRVICatalyst PharmaceuticalsNASDAQ:CPRXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 77,417 shares on 7/26/2024Ownership: 0.279%Hennion & Walsh Asset Management Inc.Bought 192,612 shares on 7/20/2024Ownership: 0.208%Michael OverdorfSold 784 sharesTotal: $4,719.68 ($6.02/share)Jennifer LewSold 1,104 sharesTotal: $6,657.12 ($6.03/share)SG Americas Securities LLCSold 6,664 shares on 7/12/2024Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions ANNX Stock Analysis - Frequently Asked Questions How have ANNX shares performed this year? Annexon's stock was trading at $4.54 on January 1st, 2024. Since then, ANNX shares have increased by 37.4% and is now trading at $6.24. View the best growth stocks for 2024 here. How were Annexon's earnings last quarter? Annexon, Inc. (NASDAQ:ANNX) released its quarterly earnings data on Monday, May, 13th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.11. When did Annexon IPO? Annexon (ANNX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen served as the underwriters for the IPO. Who are Annexon's major shareholders? Top institutional shareholders of Annexon include Bank of New York Mellon Corp (0.28%), Hennion & Walsh Asset Management Inc. (0.21%), DNB Asset Management AS (0.05%) and SG Americas Securities LLC (0.02%). Insiders that own company stock include Bain Capital Life Sciences Inv, Douglas Love, Michael Overdorf, Jennifer Lew, William H Carson and Ted Yednock. View institutional ownership trends. How do I buy shares of Annexon? Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Annexon own? Based on aggregate information from My MarketBeat watchlists, some other companies that Annexon investors own include Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Johnson & Johnson (JNJ) and RTX (RTX). This page (NASDAQ:ANNX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.